The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis
-
Published:2024-01
Issue:
Volume:193
Page:104229
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Staropoli NicolettaORCID,
Ciliberto Domenico,
Luciano Francesco,
Napoli Cristina,
Costa Martina,
Rossini Giacomo,
Arbitrio Mariamena,
Labanca Caterina,
Riillo Caterina,
Del Giudice Teresa,
Crispino Antonella,
Salvino Angela,
Galvano Antonio,
Russo Antonio,
Tassone Pierfrancesco,
Tagliaferri Pierosandro
Subject
Oncology,Hematology
Reference78 articles.
1. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012
2. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer;Aghajanian;Gynecol. Oncol.,2015
3. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: analysis of the VELIA/GOG-3005 trial;Aghajanian;Gynecol. Oncol.,2021
4. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial;Aghajanian;Gynecol. Oncol.,2022
5. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review;Alvarez Secord;Gynecol. Oncol.,2021